The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
Abstract
The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3′-azido-3′-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4 + HeLa cells. Fifty percent inhibitory dose (ID 50 ) values of 18 isolates from untreated individuals ranged between 0.01 μ M and 0.05 μ M . In contrast, most isolates from patients who had received zidovudine for 6 months or more exhibited decreased sensitivity characterized by changes in ID 50 or ID 95 values (or both), with isolates from several patients (5/15) showing 100-fold increases in ID 50 . The latter isolates were also insensitive to 3′-azido-2′,3′-dideoxyuridine; however, the isolates were still sensitive to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-2′,3′-didehydrothymidine, or phosphonoformate. It cannot be determined from this small sample of patients whether development of a less sensitive virus phenotype results in clinical resistance. Appearance of such variants was not associated with a consistent increase in viral p24 concentrations in patient plasma and did not herald any sudden deterioration in clinical status. More extensive studies are required to determine the clinical significance. Thus, it would be premature to alter any treatment protocols for HIV-infected individuals at present.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a clinical trial, its dramatic short-term effects in delaying the death of AIDS patients (109) led to its rapid approval for use, although the virus rebounded after a few months due to the appearance of mutations in RT that render it AZT resistant (110).”
From The Discovery of Reverse Transcriptase (2016) · cites this paper as [110]
Citations
Cites
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
Self-citationThe Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Hirsch, M. S., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170402 · Cited by 1,199
Self-citationInfection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay
Harada, S., Koyanagi, Y., & Yamamoto, N. (1985) · Science · doi:10.1126/science.2992081 · Cited by 857
Schmitt, F. A., Bigley, J. W., McKinnis, R., Logue, P. E., Evans, R. W., Drucker, J. L., & The AZT Collaborative Working Group* (1988) · New England Journal of Medicine · doi:10.1056/nejm198812153192404 · Cited by 396
Klecker, R. W., Collins, J. M., Yarchoan, R., Thomas, R., Jenkins, J. F., Broder, S., & Myers, C. E. (1987) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1987.49 · Cited by 381
Site-specific mutagenesis of AIDS virus reverse transcriptase
Larder, B. A., Purifoy, D. J. M., Powell, K. L., & Darby, G. (1987) · Nature · doi:10.1038/327716a0 · Cited by 312
Self-citationDevelopment of a sensitive quantitative focal assay for human immunodeficiency virus infectivity
Chesebro, B., & Wehrly, K. (1988) · Journal of Virology · doi:10.1128/jvi.62.10.3779-3788.1988 · Cited by 304
Field, H. J., & Darby, G. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.17.2.209 · Cited by 242
Self-citationISOLATION AND CHARACTERISATION OF RESISTANT HERPES SIMPLEX VIRUS AFTER ACYCLOVIR THERAPY
Burns, W., Santos, G., Saral, R., Laskin, O., Lietman, P., Mclaren, C., & Barry, D. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91620-8 · Cited by 240
Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance
Darby, G., Field, H. J., & Salisbury, S. A. (1981) · Nature · doi:10.1038/289081a0 · Cited by 204
Self-citation
Cited by
Items 701–800 of 1,000
Quan, Y., Motakis, D., Buckheit, R. W., Xu, Z., Flavin, M. T., Parniak, M. A., & Wainberg, M. A. (1999) · Antiviral Therapy · doi:10.1177/135965359900400403 · Cited by 28
Aledort, L. M., Hilgartner, M. W., Pike, M. C., Gjerset, G., Koerper, M. A., Lian, E. Y., Lusher, J. M., & Mosley, J. W. (1992) · BMJ · doi:10.1136/bmj.304.6821.212 · Cited by 28
Zidovudine and Stavudine Sequencing in HIV Treatment Planning: Findings From the CHORUS HIV Cohort
Becker, S. L., Raffanti, S. R., Hansen, N. I., Fusco, J. S., Fusco, G., Slatko, G. H., Igboko, E. F., & Graham, N. M. H. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200101010-00011 · Cited by 28
HIV seroconversion after occupational exposure despite early prophylactic zidovudine therapy
(1993) · The Lancet · doi:10.1016/0140-6736(93)92426-t · Cited by 28
Human-Phosphate-Binding-Protein inhibits HIV-1 gene transcription and replication
Cherrier, T., Elias, M. H., Jeudy, A., Gotthard, G., Douce, V. L., Hallay, H., Masson, P., Janossy, A., Candolfi, E., Rohr, O., et al. (2011) · Virology Journal · doi:10.1186/1743-422x-8-352 · Cited by 27
Chu, H., Sethy, B., Hsieh, P., & Horng, J. (2021) · Viruses · doi:10.3390/v13091756 · Cited by 27
McMahon, M. A., Shen, L., & Siliciano, R. F. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328332c54d · Cited by 27
Imamichi, T., Murphy, M. A., Adelsberger, J. W., Yang, J., Watkins, C. M., Berg, S. C., Baseler, M., Lempicki, R. A., Guo, J., Levin, J. G., et al. (2002) · Journal of Virology · doi:10.1128/jvi.77.2.1011-1020.2003 · Cited by 27
Use of Tissue Culture Cell Lines to Evaluate HIV Antiviral Resistance
Sadowska-Krowicka, H., Robinson, J. E., Clark, R. A., Hager, S., Broyles, S. T., & Pincus, S. H. (2008) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2007.0242 · Cited by 27
Cato, A. E., Qian, J. X., Hsu, A., Levy, B., Leonard, J. M., & Granneman, R. G. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1788 · Cited by 27
Mohan, P., Singh, R. P., & Baba, M. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90641-h · Cited by 27
Bozzette, S. A., & Richman, D. D. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90418-d · Cited by 27
Self-citationJourdan, F. L., LADUREE, D., & Robba, M. (1994) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.5570310208 · Cited by 27
Baba, M., Clercq, E. D., Iida, S., TANAKA, H., Nitta, I., Ubasawa, M., Takashima, H., Sekiya, K., Umezu, K., & Nakashima, H. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.12.2358 · Cited by 27
Use of Proteinase Inhibitors in Clinical Practice
Pollard, R. B. (1994) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1994.tb03628.x · Cited by 27
Wainberg, M. A., TREMBLAY, M., Rooke, R., Blain, N., Soudeyns, H., Parniak, M. A., YAO, X., LI, X., Fanning, M. M., MONTANER, J. S. G., et al. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb17855.x · Cited by 27
Inhibition of HIV-1 replication by anti-trans-activation responsive polyamide nucleotide analog
Kaushik, N., Basu, A., & Pandey, V. N. (2002) · Antiviral Research · doi:10.1016/s0166-3542(02)00024-4 · Cited by 27
Zidovudine and HIV: Mathematical models of within‐host population dynamics
McLean, A. R., & Frost, S. D. W. (1995) · Reviews in Medical Virology · doi:10.1002/rmv.1980050304 · Cited by 27
Resistance against Reverse Transcriptase Inhibitors
O’Brien, W. A. (2000) · Clinical Infectious Diseases · doi:10.1086/313858 · Cited by 27
Clinical Significance of Drug Resistance in Human Immunodeficiency Virus
Richman, D. D. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.supplement_2.s166 · Cited by 27
Self-citationAntiretroviral therapy in combination with interferon for AIDS-related Kaposi's sarcoma
Fischl, M. A. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90404-l · Cited by 27
Barlough, J. E., North, T. W., Oxford, C. L., Remington, K. M., Dandekar, S., Ellis, M., & Pedersen, N. C. (1993) · Antiviral Research · doi:10.1016/0166-3542(93)90036-i · Cited by 27
WALKER, R. E., Blacsc, R. M., Carter, C. S., Chang, L., Klein, H. G., Lane, H. C., Leilman, S. F., & Mullen, C. A. (1993) · Human Gene Therapy · doi:10.1089/hum.1993.4.5-659 · Cited by 27
Campbell, T., Young, R. K., Eron, J. J., D’Aquila, R. T., Tarpley, W. G., & Kuritzkes, D. R. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/168.2.318 · Cited by 27
da Silva-Januário, M. E., da Costa, C. S., Tavares, L., Oliveira, A. K., Januário, Y. C., de Carvalho, A. N., Cassiano, M. H. A., Rodrigues, R. L., Miller, M. E., Palameta, S., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100676 · Cited by 26
One-pot synthesis of hydrogen phosphonate derivatives of d4T and AZT
Sun, X. B., Kang, J. X., & Zhao, Y. F. (2002) · Chemical Communications · doi:10.1039/b207657h · Cited by 26
Design and synthesis of cosalane, a novel anti-HIV agent
Gołębiewski, W. M., Bader, J. P., & Cushman, M. (1993) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)80053-0 · Cited by 26
Wigg, M. D., Al-Jabri, A. A., Costa, S. S., Race, E., Bodo, B., & OXFORD, J. S. (1996) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029600700401 · Cited by 26
Cheng, J., Zhang, D., Zhou, C., & Marasco, W. A. (2003) · Leukemia Research · doi:10.1016/s0145-2126(03)00158-9 · Cited by 26
Allan, J. D., Connolly, K. J., Fitch, H., Jackson-Pope, L., McLaren, C., Canetta, R. M., & Groopman, J. E. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/16.supplement_1.s46 · Cited by 26
Arts, E. J., Quiñones‐Mateu, M. E., Albright, J. L., Marois, J.-P., Hough, C., Gu, Z., & Wainberg, M. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.4858-4865.1998 · Cited by 26
Finazzi, G., Mannucci, P. M., Lazzarin, A., Gringeri, A., Arici, C., Ciaci, D., Terzi, R., & Barbui, T. (1990) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1990.tb00422.x · Cited by 26
Du, D., Volpe, D. A., Grieshaber, C. K., & Murphy, M. J. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb04555.x · Cited by 26
Pai, S. M., Shukla, U., Grasela, T. H., Knupp, C. A., Dolin, R., Valentine, F. T., McLaren, C., Liebman, H. A., Martin, R. R., Pittman, K. A., et al. (1992) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1992.tb03832.x · Cited by 26
van Wijk, G. M. T., Hostetler, K. Y., Kroneman, E., Richman, D. D., Sridhar, C. N., Kumar, R., & van den BOSCH, H. (1994) · Chemistry and Physics of Lipids · doi:10.1016/0009-3084(94)90089-2 · Cited by 26
Self-citationMeng, T., Fischl, M. A., & Richman, D. D. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90419-e · Cited by 26
Self-citationHost-HIV-1 Interactome: A Quest for Novel Therapeutic Intervention
Shukla, E., & Chauhan, R. (2019) · Cells · doi:10.3390/cells8101155 · Cited by 25
New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?
Ndashimye, E., Reyes, P. S., & Arts, E. J. (2022) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuac040 · Cited by 25
Within-Host Virus Models with Periodic Antiviral Therapy
Leenheer, P. D. (2008) · Bulletin of Mathematical Biology · doi:10.1007/s11538-008-9359-5 · Cited by 25
Shao, X., Ekstrand, D., Bhikhabhai, R., Källander, C. F. R., & Gronowitz, J. S. (1997) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029700800209 · Cited by 25
Learning multiple evolutionary pathways from cross-sectional data
Beerenwinkel, N., Rahnenführer, J., Däumer, M., Hoffmann, D. E., Kaiser, R., Selbig, J., & Lengauer, T. (2004) · Research in Computational Molecular Biology · doi:10.1145/974614.974620 · Cited by 25
Anti-AIDS Drug Development: Challenges and Strategies
Mohan, P. (1992) · Pharmaceutical Research · doi:10.1023/a:1015882901078 · Cited by 25
HIV therapeutics: Confronting adherence
Katzenstein, D. A., Lyons, C. E., Molaghan, J. B., Ungvarski, P. J., Wolfe, G. S., & Williams, A. B. (1997) · Journal of the Association of Nurses in AIDS Care · doi:10.1016/s1055-3290(97)80008-8 · Cited by 25
Zhu, Q.-Y., Scarborough, A., Polsky, B., & Chou, T. (1996) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1996.12.507 · Cited by 25
O'Marro, S. D., Armstrong, J. A., Asuncion, C., Gueverra, L., & Ho, M. (1992) · Antiviral Research · doi:10.1016/0166-3542(92)90050-f · Cited by 25
Barry, M. G., Howe, J., Ormesher, S., Back, D., Breckenridge, A., Bergin, C. J., Mulcahy, F. M., Beeching, N. J., & Nye, F. J. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb05708.x · Cited by 25
Evaluation of the Combination Effect of Different Antiviral Compounds against HIV in Vitro
Sørensen, A. M., Nielsen, C., Mathiesen, L. R., Nielsen, J. O., & Hansen, J. S. (1993) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549309008512 · Cited by 25
Anand, R., Nayyar, S., Pitha, J., & Merril, C. R. (1990) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029000100107 · Cited by 25
Song, Q., Yang, G., Goff, S. P., & Prasad, V. R. (1992) · Journal of Virology · doi:10.1128/jvi.66.12.7568-7571.1992 · Cited by 25
Pharmacokinetics of co‐administered didanosine and stavudine in HIV‐ seropositive male patients.
Seifert, R. D., Stewart, M. L., Sramek, J. J., Conrad, J. J., Kaul, S., & Cutler, N. R. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04374.x · Cited by 25
Martin, L. N., Soike, K. F., Murphey‐Corb, M., Bohm, R. P., Roberts, E. D., Kakuk, T. J., Thaisrivongs, S., Vidmar, T. J., Ruwart, M. J., & Davio, S. R. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.6.1277 · Cited by 25
Jurriaans, S., Weverling, G. J., Goudsmit, J., van den Boogaard, J., BROK, M., van Strijp, D., Lange, J. M. A., KOOT, M., & van Gemen, B. (1995) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1995.11.473 · Cited by 25
Seki, M., Sadakata, Y., Yuasa, S., & Baba, M. (1995) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029500600201 · Cited by 25
Clinical Significance Of HIV Reverse-Transcriptase Inhibitor-Resistance Mutations
Ibe, S., & Sugiura, W. (2011) · Future Microbiology · doi:10.2217/fmb.11.7 · Cited by 24
Zidovudine: A Review of its Use in the Management of Vertically-Acquired Pediatric HIV infection
Bhana, N., Ormrod, D. J., Perry, C. M., & Figgitt, D. P. (2002) · Pediatric Drugs · doi:10.2165/00128072-200204080-00004 · Cited by 24
Papaverine hydrochloride: effects on HIV replication and T-lymphocyte cell function
Nokta, M. A., Albrecht, T., & Pollard, R. B. (1993) · Immunopharmacology · doi:10.1016/0162-3109(93)90010-n · Cited by 24
Turner, D., Brenner, B., & Wainberg, M. A. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh009 · Cited by 24
Carter, W. A., Ventura, D., Shapiro, D. E., Strayer, D. R., Gillespie, D. H., & Hubbell, H. R. (1991) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(91)90127-s · Cited by 24
A mathematical model of vaccination against HIV to prevent the development of AIDS
Nowak, M. A., & McLean, A. R. (1991) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1991.0136 · Cited by 24
Nurpeisov, V., Hurwitz, S. J., & Sharma, P. L. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.7.3306-3311.2003 · Cited by 24
Singh, S., Malik, B., & Sharma, D. K. (2007) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2007.00478.x · Cited by 24
Antiretroviral drug resistance in HIV-1
Hanna, G. J., & D’Aquila, R. T. (1999) · Current Infectious Disease Reports · doi:10.1007/s11908-999-0032-4 · Cited by 24
Swayze, E. E., Peiris, S. M., Kucera, L. S., White, E. L., Wise, D. S., Drach, J. C., & Townsend, L. B. (1993) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)81224-5 · Cited by 24
Xie, H. J., Voronkov, M. V., Liotta, D. C., Korba, B. A., Schinazi, R. F., Richman, D. D., & Hostetler, K. Y. (1995) · Antiviral Research · doi:10.1016/0166-3542(95)00042-k · Cited by 24
Self-citationChapter 16 Recent Advances in Anti-retroviral Chemotherapy for AIDS
Norbeck, D. W. (1990) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60020-2 · Cited by 24
Baba, M., Ito, M., Shigeta, S., TANAKA, H., MIYASAKA, T., Ubasawa, M., Umezu, K., Walker, R. T., & Clercq, E. D. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.7.1430 · Cited by 24
Moyle, G. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.8.943 · Cited by 24
Pizzo, P. A. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90416-b · Cited by 24
Zhao, N., Wang, G., Das, A. T., & Berkhout, B. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01486-17 · Cited by 23
A fluorescent in situ hybridization method in flow cytometry to detect HIV-1 specific RNA
Borzì, R. M., Piacentini, A., Monaco, M. C., Lisignoli, G., Degrassi, A., Cattini, L., Santi, S., & Facchini, A. (1996) · Journal of Immunological Methods · doi:10.1016/0022-1759(96)00070-1 · Cited by 23
Newman, R. A., Chen, W., & Madden, T. L. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980122d · Cited by 23
HIV-1 genotyping: comparison of two commercially available assays
Stürmer, M., Berger, A., & Preiser, W. (2004) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.4.3.281 · Cited by 23
HIV therapy: Managing resistance
Wodarz, D., & Nowak, M. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8193 · Cited by 23
Adverse effects of antiretroviral therapy: focus on orofacial effects
Dios, P. D., & Scully, C. M. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.4.307 · Cited by 23
In Vitro Evaluation of Experimental Agents for Anti‐ HIV Activity
Richman, D. D., Johnson, V. A., Mayers, D. M., Shirasaka, T., O'Brien, M. C., & Mitsuya, H. (1993) · Current Protocols in Immunology · doi:10.1002/0471142735.im1209s08 · Cited by 23
Self-citationLeal, E. D. S., Holmes, E. C., & Zanotto, P. M. D. A. (2004) · Virology · doi:10.1016/j.virol.2004.04.004 · Cited by 23
A fossil record of zidovudine resistance in transmitted isolates of HIV-1
Kuritzkes, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251559398 · Cited by 23
Cho, Y.-K., Sung, H., Ahn, S. H., Bae, I. G., Woo, J. H., Won, Y. H., Kim, D. G., & Kang, M. W. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1319-1325.2002 · Cited by 23
Goodwin, S. D., Fletcher, C. V., Shelton, M. J., O'Donnell, A. M., & Morse, G. D. (1993) · Annals of Pharmacotherapy · doi:10.1177/106002809302700416 · Cited by 23
Rosowsky, A., Fu, H., Pai, N. N., Mellors, J. W., Richman, D. D., & Hostetler, K. Y. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970172f · Cited by 23
Self-citationLambert, D. M., BARTUS, H. F., Fernandez, A. V., Bratby-Anders, C., Leary, J. J., Dreyer, G. B., Metcalf, B. W., & Petteway, S. R. (1993) · Antiviral Research · doi:10.1016/0166-3542(93)90011-7 · Cited by 23
McGuigan, C., Kinchington, D., Wang, M. F., Nicholls, S. R., Nickson, C., Galpin, S. A., Jeffries, D. J., & OʼConnor, T. J. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81580-s · Cited by 23
Reedijk, M., Boucher, C. A., van Bommel, T., Ho, D. D., Tzeng, T.-B., Séréni, D., Veyssier, P., Jurriaans, S., Granneman, R. G., & Hsu, A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.7.1559 · Cited by 23
Hitchcock, M. J. M., Woods, K. L., Boeck, H. D., & Ho, H.-T. (1990) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029000100507 · Cited by 23
HIV-1 Drug Resistance: Molecular Pathogenesis and Laboratory Monitoring
D’Aquila, R. T. (1994) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30385-8 · Cited by 23
Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication
Ding, S., Noronha, J., & Joshi, S. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.13.3270 · Cited by 23
Kretzschmar, B., Nowrouzi, A., Hartl, M. J., Gärtner, K., Wiktorowicz, T., Herchenröder, O., Kanzler, S., Rudolph, W. W., Mergia, A., Wöhrl, B. M., et al. (2007) · Virology · doi:10.1016/j.virol.2007.08.025 · Cited by 22
Medlin, H. K., Zhu, Y. Q., Remington, K. M., Phillips, T. R., & North, T. W. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.953 · Cited by 22
OTAKE, T., Schols, D., Witvrouw, M., Naesens, L. M. J., Nakashima, H., Moriya, T., Kurita, H., Matsumoto, K., Noboru, U. E. B. A., & Clercq, E. D. (1994) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029400500303 · Cited by 22
Clinical pharmacology of zidovudine and other 2?,3?-dideoxynucleoside analogues
Kamali, F. (1993) · Journal of Molecular Medicine · doi:10.1007/bf00186630 · Cited by 22
2′,3′-Dideoxycytidine metabolism in a new drug-resistant cell line
Magnani, M., Brandi, G., Casabianca, A., Fraternale, A., Schiavano, G. F., Rossi, L., & Chiarantini, L. (1995) · Biochemical Journal · doi:10.1042/bj3120115 · Cited by 22
The transformation of HIV therapy: One pill once a day
Choudhary, M. C., & Mellors, J. W. (2022) · Antiviral Therapy · doi:10.1177/13596535211062396 · Cited by 21
Asmal, M., Whitney, J. B., Luedemann, C., Carville, A., Steen, R., Letvin, N. L., & Geiben-Lynn, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048234 · Cited by 21
Jiang, T., & Chen, X. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17041395 · Cited by 21
Molecular epidemiology in the HIV and SARS-CoV-2 pandemics
Lorenzo-Redondo, R., Ozer, E. A., Achenbach, C. J., D’Aquila, R. T., & Hultquist, J. F. (2020) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000660 · Cited by 21
Mathematical Modeling of HIV-1 Infection and Drug Therapy
Rong, L., Feng, Z., & Perelson, A. S. (2008) · Springer eBooks · doi:10.1007/978-3-540-76784-8_3 · Cited by 21
Kawahata, T., OTAKE, T., Mori, H., Kojima, Y., Oishi, I., Shinichi, O. K. A., Fukumori, Y., & Sano, K. (2002) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020201300503 · Cited by 21
Wodarz, D., & Nowak, M. A. (2000) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2000.0643 · Cited by 21
Community treatment of HIV-1: initial stage and asymptotic dynamics
Hsieh, Y., & Velasco‐Hernández, J. X. (1995) · Biosystems · doi:10.1016/0303-2647(94)01482-m · Cited by 21
Quan, Y., Inouye, P., Liang, C., Rong, L., Götte, M., & Wainberg, M. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21918 · Cited by 21
Metadata
- Authors
- Larder, B. A., Darby, G., & Richman, D. D.
- Affiliations
- Wellcome Trust (GB)
- University of California San Diego (US)
- ORCID
- Richman, Douglas D.
- Venue
- Science
- Published
- 1989-03-31
- Volume
- 243
- Issue
- 4899
- Pages
- 1731-1734
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2086462809
- Cited by
- 1,559
- References
- 22
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 3 · 2023: 10 · 2022: 12 · 2021: 8 · 2020: 9 · 2019: 12 · 2018: 6 · 2017: 13 · 2016: 16 · 2015: 10 · 2014: 21 · 2013: 13 · 2012: 16
- FWCI
- 157.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HB-6-7019)
- National Institute of Allergy and Infectious Diseases (AI-62548, AI-52578)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- HIV drug resistance, zidovudine resistance, AIDS, AIDS-related complex, antiretroviral therapy, 2',3'-dideoxycytidine, phosphonoformate
- MeSH terms
- Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Drug Resistance, HeLa Cells, HIV, Humans, Microbial Sensitivity Tests, Phosphonoacetic Acid, Viral Plaque Assay, Retroviridae Proteins, Virus Replication, Zidovudine, Dideoxynucleosides, Zalcitabine, HIV Core Protein p24, Foscarnet, Reverse Transcriptase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.